Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CADL

Candel Therapeutics Inc

Dec 08 • 04:00PM ET

5.45

+0.12 2.25 %

Healthcare • Biotechnology • USA • NASD

Peers: ADAP IMTX XBIT ZNTL ATHA MRNS PPBT BLRX CYPH ADIL

| Held by: VTI IWM VXF IWO VTWO IWC VTWG IWN SBIO RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.56	Insider Own	25.21%	Shs Outstand	54.90M	Perf Week	21.65%
Market Cap	299.20M	Forward P/E	-	EPS next Y	-0.99	Insider Trans	-0.01%	Shs Float	41.06M	Perf Month	10.32%
Enterprise Value	219.45M	PEG	-	EPS next Q	-0.25	Inst Own	36.98%	Short Float	20.32%	Perf Quarter	9.66%
Income	-22.76M	P/S	-	EPS this Y	76.06%	Inst Trans	-0.79%	Short Ratio	10.71	Perf Half Y	-7.00%
Sales	0.00M	P/B	3.73	EPS next Y	-138.27%	ROA	-39.54%	Short Interest	8.34M	Perf YTD	-37.21%
Book/sh	1.46	P/C	3.44	EPS next 5Y	35.44%	ROE	-70.17%	52W High	14.60 -62.67%	Perf Year	23.02%
Cash/sh	1.58	P/FCF	-	EPS past 3/5Y	-11.43% -43.86%	ROIC	-27.53%	52W Low	4.25 28.24%	Perf 3Y	202.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.81% 6.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	68.53%	Oper. Margin	-	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.25	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	61.92	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	8.25	EPS Q/Q	38.27%	SMA20	14.32%	Beta	-0.92	Target Price	18.62
Payout	-	Debt/Eq	0.09	Sales Q/Q	-	SMA50	4.27%	Rel Volume	1.14	Prev Close	5.33
Employees	38	LT Debt/Eq	0.03	Earnings	Nov 13 BMO	SMA200	-5.38%	Avg Volume	779.39K	Price	5.45
IPO	Jul 27, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.39% -	Trades		Volume	888,573	Change	2.25%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-28-25	Initiated	Stephens	Overweight	$15
Sep-03-25	Downgrade	BofA Securities	Buy → Neutral	$7
Jun-30-25	Resumed	H.C. Wainwright	Buy	$23
Feb-20-25	Initiated	Citigroup	Buy	$25
Feb-19-25	Initiated	Canaccord Genuity	Buy	$20
Feb-07-25	Initiated	BofA Securities	Buy	$15
Dec-02-22	Initiated	H.C. Wainwright	Buy	$11
Nov-19-21	Initiated	BMO Capital Markets	Outperform	$18
Aug-23-21	Initiated	UBS	Buy	$9
Aug-23-21	Initiated	Jefferies	Buy	$22
Aug-23-21	Initiated	Credit Suisse	Outperform	$15

Show Previous Ratings

Nov-17-25 04:05PM	Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 (GlobeNewswire)
Nov-13-25 08:25AM	Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -6.30%
Nov-04-25 09:00AM	Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors (GlobeNewswire)
Nov-03-25 08:05AM	Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-16-25 08:05AM	Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board (GlobeNewswire) -9.29%
08:31AM	Loading…
Oct-15-25 08:31AM	Candel Therapeutics announces interim data from phase 1b CAN-3110 trial (TipRanks)
Oct-14-25 08:10AM	Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer (PR Newswire) -10.74%
08:10AM	Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. (GlobeNewswire)
08:05AM	Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine (GlobeNewswire)
Oct-03-25 09:05AM	Candel Therapeutics to Present at the SITC 2025 Annual Meeting (GlobeNewswire)
Sep-29-25 08:05AM	Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 (GlobeNewswire)
Sep-17-25 08:05AM	Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 (GlobeNewswire)
Sep-02-25 08:05AM	Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board (GlobeNewswire)
Aug-28-25 08:05AM	Candel Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-14-25 08:05AM	Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) -5.63%
08:05AM	Loading…
Jul-30-25 08:05AM	Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-25-25 08:23AM	Candel Therapeutics' CAN-2409 gains EMA orphan designation (Pharmaceutical Business Review)
Jul-24-25 08:05AM	Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jul-09-25 08:05AM	Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution (GlobeNewswire) +16.22%
Jun-25-25 12:00PM	Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Jun-24-25 09:05AM	Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock (GlobeNewswire)
Jun-23-25 08:05AM	Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer (GlobeNewswire)
Jun-06-25 08:05AM	Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire) +8.83%
Jun-02-25 09:55AM	Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? (Zacks)
May-29-25 11:41PM	Candel Therapeutics, Inc. (CADL)'s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer (Insider Monkey) -6.84%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
May-28-25 08:05AM	Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer (GlobeNewswire) +6.07%
May-27-25 08:05AM	Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation (GlobeNewswire)
May-23-25 01:46AM	Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 (Insider Monkey)
May-22-25 05:05PM	Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 (GlobeNewswire)
10:00AM	Loading…
May-19-25 10:00AM	Best Momentum Stocks to Buy for May 19th (Zacks) +6.54%
07:49AM	New Strong Buy Stocks for May 19th (Zacks)
May-16-25 09:55AM	Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know (Zacks)
May-13-25 08:05AM	Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire) +7.68%
May-06-25 08:05AM	Candel Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -7.83%
Apr-23-25 04:05PM	Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 (GlobeNewswire) +5.04%
Apr-01-25 08:01AM	Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients (GlobeNewswire)
Mar-27-25 03:46PM	Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients (Benzinga) -7.33%
Mar-26-25 04:05PM	Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment (GlobeNewswire) -8.76%
Mar-25-25 09:55AM	Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now (Zacks) -5.08%
Mar-20-25 08:00AM	Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409 (GlobeNewswire) -7.30%
Mar-18-25 08:00AM	Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board (GlobeNewswire)
Mar-13-25 04:15PM	Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire) +10.20%
Feb-25-25 01:58PM	Candel Therapeutics stock drops despite OS improvement in PDAC trial (Clinical Trials Arena) -23.49%
08:00AM	Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire)
Jan-13-25 08:00AM	Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025 (GlobeNewswire) -5.01%
Jan-09-25 01:44AM	After layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win (Pharma Voice)
Dec-19-24 01:44PM	Hedge Fund and Insider Trading News: Simon Sadler, Stanley Druckenmiller, Warren Buffett, Caxton Associates, Millennium Management, Saba Capital, Candel Therapeutics Inc (CADL), NVIDIA Corp (NVDA), and More (Insider Monkey) +52.53%
Dec-16-24 04:01PM	Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.81% +7.23%
Dec-12-24 11:00PM	Candel Therapeutics Announces Pricing of Public Offering (GlobeNewswire) +26.45% -31.12%
04:51PM	Candel Therapeutics Announces $80 Million Proposed Public Offering (GlobeNewswire)
Dec-11-24 04:09PM	Candel Skyrockets 68% On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily) +68.11%
01:07PM	Candel Therapeutics Prostate Cancer Therapy Shows Promise (Exec Edge)
11:54AM	Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug (Investor's Business Daily)
10:32AM	Candel Therapeutics stock up 172% after Phase III prostate cancer success (Clinical Trials Arena)
09:19AM	Candel Therapeutics Stock Surges Over 100% - Here's Why (Benzinga)
07:00AM	Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival (GlobeNewswire)
Nov-14-24 08:00AM	Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-07-24 08:00AM	Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024 (GlobeNewswire)
Nov-05-24 09:00AM	Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma (GlobeNewswire)
Oct-29-24 08:59AM	Candel Therapeutics Advances in Cancer Treatment Trials (TipRanks)
Oct-28-24 08:00AM	Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC) (GlobeNewswire)
Oct-04-24 09:00AM	Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting (GlobeNewswire)
Sep-04-24 08:00AM	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors (GlobeNewswire)
Sep-03-24 08:00AM	Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.52%
Aug-13-24 08:00AM	Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Jun-18-24 08:00AM	Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire) -6.93%
Jun-14-24 08:30AM	Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments (News Direct)
07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-11-24 08:00AM	Candel Therapeutics to Join Russell 3000 Index (GlobeNewswire) +7.40%
Jun-07-24 08:30AM	Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers (News Direct)
Jun-03-24 08:30AM	Candel Therapeutics (NASDAQ: CADL) Reports Positive Data From Phase 2 Trial Of CAN-2409 In Borderline Resectable Pancreatic Cancer (News Direct) -5.96%
May-30-24 08:00AM	FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma (GlobeNewswire)
May-28-24 11:07AM	Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why (Zacks) +9.62%
May-24-24 11:42AM	Candel (CADL) Reports Upbeat Data From Lung Cancer Study (Zacks) -27.03%
May-23-24 05:00PM	Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting (GlobeNewswire)
11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-22-24 08:00AM	Candel Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -13.77%
May-20-24 08:00AM	Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting (GlobeNewswire)
May-15-24 11:14AM	Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection (PR Newswire) +30.84%
May-14-24 01:53PM	CADL Stock Earnings: Candel Therapeutics Reported Results for Q1 2024 (InvestorPlace)
08:00AM	Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire) -7.94%
Apr-25-24 08:00AM	Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire) +6.28%
Apr-12-24 10:00AM	Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag (Zacks) -8.52%
Apr-11-24 09:00AM	Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer (GlobeNewswire) +42.75%
Apr-09-24 08:00AM	Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors (GlobeNewswire) -20.84%
Apr-05-24 12:10PM	Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study (Zacks)
Apr-04-24 12:24PM	After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study (Benzinga) +280.95%
08:00AM	Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer (GlobeNewswire)
Mar-28-24 04:05PM	Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma (GlobeNewswire) +10.76%
01:53PM	CADL Stock Earnings: Candel Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
08:05AM	Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-15-24 08:15AM	Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors (News Direct)
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 04:30PM	Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate (GlobeNewswire)
Feb-13-24 07:30AM	CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma (GlobeNewswire) +29.50%
Feb-05-24 08:00AM	Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts (GlobeNewswire)

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nichols William Garrett	Chief Medical Officer	Jul 28 '25	Option Exercise	1.29	937	1,209	53,430	Jul 30 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jul 28 '25	Sale	6.98	937	6,540	52,493	Jul 30 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jun 30 '25	Option Exercise	1.29	781	1,007	53,274	Jul 02 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jun 30 '25	Sale	5.04	781	3,936	52,493	Jul 02 04:30 PM
WILLIAM GARRETT NICHOLS	Officer	Jun 30 '25	Proposed Sale	4.90	3,593	17,606		Jun 30 04:19 PM
Nichols William Garrett	Chief Medical Officer	Mar 18 '25	Option Exercise	1.90	18,489	35,127	97,809	Mar 20 04:36 PM
Nichols William Garrett	Chief Medical Officer	Mar 18 '25	Sale	8.76	45,316	396,995	52,493	Mar 20 04:36 PM
Barone Francesca	Chief Scientific Officer	Mar 18 '25	Option Exercise	1.55	18,000	27,900	128,673	Mar 20 04:36 PM
Barone Francesca	Chief Scientific Officer	Mar 18 '25	Sale	8.76	32,146	281,673	96,527	Mar 20 04:36 PM
Tak Paul Peter	Chief Executive Officer	Mar 18 '25	Sale	8.77	25,772	226,023	226,140	Mar 20 04:35 PM
Tak Paul Peter	Chief Executive Officer	Mar 19 '25	Sale	9.00	400	3,601	225,740	Mar 20 04:35 PM
Tyagarajan Seshu	Chief Technology Officer	Mar 17 '25	Sale	8.82	31,278	275,947	85,512	Mar 19 04:12 PM
Schoch Charles	See Remarks	Mar 17 '25	Sale	8.83	5,000	44,169	38,038	Mar 19 04:06 PM
FRANCESCA BARONE	Officer	Mar 18 '25	Proposed Sale	8.83	32,146	283,849		Mar 18 04:29 PM
PAUL PETER TAK	Director	Mar 18 '25	Proposed Sale	8.83	74,106	654,356		Mar 18 04:29 PM
WILLIAM GARRETT NICHOLS	Officer	Mar 18 '25	Proposed Sale	8.83	45,316	400,140		Mar 18 04:28 PM
SESHU TYAGARAJAN	Officer	Mar 17 '25	Proposed Sale	8.75	31,278	273,682		Mar 17 04:29 PM
CHARLES SCHOCH	Officer	Mar 17 '25	Proposed Sale	8.75	5,000	43,750		Mar 17 04:29 PM
Barone Francesca	Chief Scientific Officer	Jan 15 '25	Sale	7.22	13,534	97,783	110,673	Jan 17 04:30 PM
Tyagarajan Seshu	Chief Technology Officer	Jan 15 '25	Sale	7.22	14,322	103,476	96,790	Jan 17 04:30 PM
Schoch Charles	See Remarks	Jan 15 '25	Sale	7.22	9,511	68,717	43,038	Jan 17 04:30 PM
Tak Paul Peter	Chief Executive Officer	Jan 15 '25	Sale	7.22	21,704	156,811	251,912	Jan 17 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jan 15 '25	Sale	7.22	10,428	75,342	79,320	Jan 17 04:30 PM
Tyagarajan Seshu	Officer	Jan 15 '25	Proposed Sale	7.84	13,177	103,308		Jan 15 08:30 AM
Barone Francesca	Officer	Jan 15 '25	Proposed Sale	7.84	12,452	97,624		Jan 15 08:30 AM
Nichols William Garrett	Officer	Jan 15 '25	Proposed Sale	7.86	9,564	75,217		Jan 15 08:30 AM
Schoch Charles	Officer	Jan 15 '25	Proposed Sale	7.84	8,751	68,608		Jan 15 08:30 AM
Tak Paul Peter	Officer	Jan 15 '25	Proposed Sale	7.84	19,970	156,565		Jan 15 08:30 AM
Barone Francesca	Chief Scientific Officer	Jan 08 '25	Sale	8.22	13,673	112,367	124,207	Jan 10 04:30 PM
Schoch Charles	See Remarks	Jan 08 '25	Sale	8.22	9,971	81,944	52,549	Jan 10 04:30 PM
Tak Paul Peter	Chief Executive Officer	Jan 08 '25	Sale	8.22	21,172	173,996	273,616	Jan 10 04:30 PM
Tyagarajan Seshu	Chief Technology Officer	Jan 08 '25	Sale	8.22	14,545	119,534	111,112	Jan 10 04:30 PM
Nichols William Garrett	Chief Medical Officer	Jan 08 '25	Sale	8.22	10,799	88,749	89,748	Jan 10 04:30 PM
Tyagarajan Seshu	Officer	Jan 08 '25	Proposed Sale	8.35	14,297	119,380		Jan 08 08:29 AM
Tak Paul Peter	Officer	Jan 08 '25	Proposed Sale	8.35	20,811	173,772		Jan 08 08:28 AM
Nichols William Garrett	Officer	Jan 08 '25	Proposed Sale	8.35	10,614	88,627		Jan 08 08:28 AM
Barone Francesca	Officer	Jan 08 '25	Proposed Sale	8.35	13,440	112,224		Jan 08 08:27 AM
Schoch Charles	Officer	Jan 08 '25	Proposed Sale	8.35	9,801	81,838		Jan 08 08:27 AM
Manning Paul B	Director	Dec 16 '24	Buy	6.00	1,250,000	7,500,000	1,303,752	Dec 18 04:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CADL

Candel Therapeutics Inc

Upgrade your FINVIZ experience